Renovaro says Predictive Oncology terminates merger transaction

Renovaro BioSciences (RENB) announced that it received an email from Predictive Oncology (POAI) terminating the merger transaction. The company added, “Renovaro’s position is that POI must comply with the binding obligations thereunder and enter into an exclusive License Agreement as required in each of the Binding Agreements. Renovaro notes that POI is in breach of the Binding Agreements and has caused substantial damage to Renovaro for which it will seek redress. Failure to enter into an exclusive License Agreement on the terms set forth in the Binding Agreement on or before April 10, 2025, will cause Renovaro to seek all its legal remedies to recover all its damages and/or seek additional remedies to fully redress the breaches.”